- Home
- LCTX vs LGCY Comparison
LCTX vs LGCY Comparison
Compare LCTX & LGCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- LGCY
- Stock Information
- Founded
- LCTX 1990
- LGCY 2009
- Country
- LCTX United States
- LGCY United States
- Employees
- LCTX N/A
- LGCY N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- LGCY
- Sector
- LCTX Health Care
- LGCY
- Exchange
- LCTX Nasdaq
- LGCY NYSE
- Market Cap
- LCTX 107.3M
- LGCY 117.7M
- IPO Year
- LCTX N/A
- LGCY 2024
- Fundamental
- Price
- LCTX $1.03
- LGCY $11.81
- Analyst Decision
- LCTX Strong Buy
- LGCY Strong Buy
- Analyst Count
- LCTX 5
- LGCY 2
- Target Price
- LCTX $4.20
- LGCY $10.65
- AVG Volume (30 Days)
- LCTX 1.6M
- LGCY 93.9K
- Earning Date
- LCTX 08-07-2025
- LGCY 05-15-2025
- Dividend Yield
- LCTX N/A
- LGCY N/A
- EPS Growth
- LCTX N/A
- LGCY 21.53
- EPS
- LCTX N/A
- LGCY 0.62
- Revenue
- LCTX $9,557,000.00
- LGCY $58,970,210.00
- Revenue This Year
- LCTX N/A
- LGCY $33.77
- Revenue Next Year
- LCTX $232.66
- LGCY $24.88
- P/E Ratio
- LCTX N/A
- LGCY $19.28
- Revenue Growth
- LCTX 19.42
- LGCY 37.92
- 52 Week Low
- LCTX $0.37
- LGCY $3.60
- 52 Week High
- LCTX $1.21
- LGCY $12.30
- Technical
- Relative Strength Index (RSI)
- LCTX 53.25
- LGCY N/A
- Support Level
- LCTX $0.93
- LGCY N/A
- Resistance Level
- LCTX $1.02
- LGCY N/A
- Average True Range (ATR)
- LCTX 0.08
- LGCY 0.00
- MACD
- LCTX -0.01
- LGCY 0.00
- Stochastic Oscillator
- LCTX 35.71
- LGCY 0.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.